Status:
TERMINATED
Study to Assess Monoclonal B-Cell Lymphocytosis in Individuals With Chronic Hepatitis C
Lead Sponsor:
Mayo Clinic
Conditions:
Chronic Viral Hepatitis C
Monoclonal B-Cell Lymphocytosis
Eligibility:
All Genders
Brief Summary
This study evaluates the incidence of monoclonal B-cell lymphocytosis MBL) in patients with chronic hepatitis C and to determine if monoclonal b-cell lymphocytosis is affected by treatment for hepatit...
Detailed Description
PRIMARY OBJECTIVES: I. To determine the prevalence of MBL in patients with chronic hepatitis C who are to begin therapy with directly acting antiviral (DAA), and compare with clinic controls who are ...
Eligibility Criteria
Inclusion
- Individuals with chronic hepatitis C who are to begin therapy with DAA
- Willing to submit a peripheral blood sample at baseline, end of therapy, 12 weeks after the end of therapy, and 52 weeks from baseline
Exclusion
- Individuals with chronic hepatitis C who have cirrhosis
- Individuals with chronic hepatitis C who have a past history of a lymphoproliferative disorder AND for which they received chemotherapy
Key Trial Info
Start Date :
November 14 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 3 2025
Estimated Enrollment :
29 Patients enrolled
Trial Details
Trial ID
NCT06564051
Start Date
November 14 2017
End Date
December 3 2025
Last Update
January 6 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905